Compare Panacea Biotech with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs TORRENT PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH TORRENT PHARMA PANACEA BIOTECH/
TORRENT PHARMA
 
P/E (TTM) x 15.8 37.0 42.8% View Chart
P/BV x 6.2 9.4 65.8% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   TORRENT PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
TORRENT PHARMA
Mar-19
PANACEA BIOTECH/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3541,964 18.0%   
Low Rs1381,245 11.1%   
Sales per share (Unadj.) Rs74.6453.4 16.4%  
Earnings per share (Unadj.) Rs6.725.8 25.9%  
Cash flow per share (Unadj.) Rs15.562.3 24.9%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs57.2279.2 20.5%  
Shares outstanding (eoy) m61.25169.22 36.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.33.5 93.2%   
Avg P/E ratio x36.862.2 59.2%  
P/CF ratio (eoy) x15.925.8 61.6%  
Price / Book Value ratio x4.35.7 74.8%  
Dividend payout %065.9 0.0%   
Avg Mkt Cap Rs m15,061271,513 5.5%   
No. of employees `0002.313.6 17.0%   
Total wages/salary Rs m1,47114,038 10.5%   
Avg. sales/employee Rs Th1,973.65,642.6 35.0%   
Avg. wages/employee Rs Th635.61,032.4 61.6%   
Avg. net profit/employee Rs Th176.8320.9 55.1%   
INCOME DATA
Net Sales Rs m4,56776,728 6.0%  
Other income Rs m45571 7.9%   
Total revenues Rs m4,61277,299 6.0%   
Gross profit Rs m2,03019,831 10.2%  
Depreciation Rs m5406,177 8.7%   
Interest Rs m1,0485,038 20.8%   
Profit before tax Rs m4869,187 5.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m771,254 6.2%   
Profit after tax Rs m4094,363 9.4%  
Gross profit margin %44.425.8 172.0%  
Effective tax rate %15.913.6 116.2%   
Net profit margin %9.05.7 157.5%  
BALANCE SHEET DATA
Current assets Rs m2,41550,375 4.8%   
Current liabilities Rs m9,07751,653 17.6%   
Net working cap to sales %-145.9-1.7 8,760.4%  
Current ratio x0.31.0 27.3%  
Inventory Days Days6592 70.7%  
Debtors Days Days7168 103.8%  
Net fixed assets Rs m8,33383,648 10.0%   
Share capital Rs m61846 7.2%   
"Free" reserves Rs m3,44346,397 7.4%   
Net worth Rs m3,50447,244 7.4%   
Long term debt Rs m46139,129 1.2%   
Total assets Rs m13,755141,209 9.7%  
Interest coverage x1.52.8 51.8%   
Debt to equity ratio x0.10.8 15.9%  
Sales to assets ratio x0.30.5 61.1%   
Return on assets %10.66.7 159.2%  
Return on equity %11.79.2 126.4%  
Return on capital %38.712.3 313.7%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,20322,103 5.4%   
Fx outflow Rs m4675,522 8.5%   
Net fx Rs m73616,581 4.4%   
CASH FLOW
From Operations Rs m1,04917,981 5.8%  
From Investments Rs m-54-2,413 2.2%  
From Financial Activity Rs m-1,011-13,145 7.7%  
Net Cashflow Rs m-202,380 -0.8%  

Share Holding

Indian Promoters % 74.5 71.5 104.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 7.0 8.5%  
FIIs % 1.3 12.6 10.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 8.8 268.2%  
Shareholders   10,259 26,511 38.7%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


May 7, 2021 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS